Keys to unlock cancer: Targeted therapy

Oncology Nursing Forum

Volumn 32, Issue 5, 2005, Pages 935-940

  Viele, Carol S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

DRUG DELIVERY SYSTEM; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NURSING; ONCOLOGY NURSING; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; LIGANDS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOLOGIC NURSING; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745368070     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/05.ONF.935-940     Document Type: Article

References (24)

1. D'Amato, R.J., Loughnan, M.S., Flynn, E., & Folkman, J. (1994). Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 91, 4082-4085.
2. Dvorak, H.F., Brown, L.F., Detmar, M., & Dvorak, A. (1995). Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology, 146, 1029-1039.
3. Ellis, L.M. (2004a). Angiogenesis and its role in colorectal tumor and metastasis formation. Seminars in Oncology, 31(6, Suppl. 17), 3-9.
4. Ellis, L.M. (2004b). The biology of VEGF and tumor angiogenesis. Horizons in Cancer Therapeutics: From Bench to Bedside, 5, 4-10.
5. Franson, P.J., & Lapka, D.V. (2005). Antivascular endothelial growth factor monoclonal antibody therapy: A promising paradigm in colorectal cancer. Clinical Journal of Oncology Nursing, 9, 55-60.
6. Genentech, Inc. (2004). Avastin™ (bevacizumab). Retrieved March 20, 2005, from http://www.gene.com/gene/products/information/oncology/avastin
7. Harari, P.M. (2004). Epidermal growth factor receptor inhibition strategies in oncology. Endocrine-Related Cancer, 11, 689-708.
8. Hicklin, D.J., & Ellis, L.M. (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology, 23, 1011-1027.
9. Hoff, P.M. (2004). Future directions in the use of antiangiogenic agents in patients with colorectal cancer. Seminars in Oncology, 31(6, Suppl. 17), 17-21.
10. Hong, W., & Ullrich, A. (2000). Oncology biotherapeutics: The role of EGFR in solid tumors and implications for therapy. Retrieved July 25, 2005, from www.merck.es/oncologia/oncobio/oncobio_2001_vol1_no1.pdf
11. Ignoffo, R.J. (2004). Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. American Journal of Health-System Pharmacy, 61(21, Suppl. 5), S21-S26.
12. Iqbal, S., & Lenz, H.J. (2004). Angiogenesis inhibitors in the treatment of colorectal cancer. Seminars in Oncology, 31(6, Suppl. 17), 10-16.
13. Kohler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495-497.
14. Krozely, P. (2004). Epidermal growth factor receptor tyrosine kinase inhibitors: Evolving role in the treatment of solid tumors. Clinical Journal of Oncology Nursing, 8, 163-168.
15. Kumar, S., Witzig, T.E., & Rajkumar, S.V. (2004). Thalidomid: Current role in the treatment of non-plasma cell malignancies. Journal of Clinical Oncology, 22, 2477-2488.
16. Mendelsohn, J. (2001). The epidermal growth factor receptor as a target for cancer therapy. Endocrine-Related Cancer, 8, 3-9.
17. Nicholson, R.I., Gee, J.M., & Harper, M.E. (2001). EGFR and cancer prognosis. European Journal of Cancer, 37(Suppl. 4), S9-S15.
18. Pizzo, B. (2004). New directions in oncology nursing care: Focus on gefitinib in patients with lung cancer. Clinical Journal of Oncology Nursing, 8, 385-392.
19. U.S. Food and Drug Administration. (2004). FDA statement on Iressa. Retrieved April 12, 2005, from http://www.fda.gov/bbs/topics/news/2004/new01145. html
20. U.S. Food and Drug Administration. (2005a). Erbitux (cetuximab). Retrieved April 15, 2004, from http://www.fda.gov/cder/drug/infopage/erbitux/ default.htm
21. U.S. Food and Drug Administration. (2005b). Tarceva®. Retrieved April 24, 2005, from http://www.fda.gov/cder/consumerinfo/DRUGINFO/TARCEVA.htm
22. Wells, A. (1999). EGF receptor. International Journal of Biochemistry and Cell Biology, 31, 637-643.
23. Wilkes, G.M., & Barton-Burke, M. (Eds.). (2005). 2005 oncology nursing drug handbook. Sudbury, MA: Jones and Bartlett.
24. Yarden, Y. (2001). The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities. European Journal of Cancer, 57(Suppl. 4), S3-S8.